1. 首页
  2. 产品目录

AGI-5198,突变体异柠檬酸脱氢酶1（mIDH1）的有效抑制剂

AGI-5198 （订货以英文为准）

编号：A126546
CAS号：1355326-35-0
分子式：C27H31FN4O2
分子量：462.56
货号 品牌 包装 目录价 您的价格 库存 数量 购买
A126546-25mg 阿拉丁 25mg ¥378.90
请登录
A126546-5mg 阿拉丁 5mg ¥165.90
请登录
A126546-100mg 阿拉丁 100mg ¥871.90
请登录
产品名称 AGI-5198
中文名称 AGI-5198,突变体异柠檬酸脱氢酶1（mIDH1）的有效抑制剂
CAS号 1355326-35-0
分子式（M.F.） C27H31FN4O2
分子量（M.W.） 462.56
储存条件 -20°C储存
溶解性DMSO 24 mg/mL Water <1 mg/mL Ethanol 14 mg/mL
存贮条件储存温度-20°C
应用AGI-5198(IDH C35)是剂量依赖的R132H-IDH1抑制剂
产品介绍AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
备注AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
生化机理Description:IC50 Value: N/AAGI-5198, a novel R132H-IDH1 inhibitor, identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG). The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy. Isocitrate dehydrogenase 1 (IDH1) is one potential drug target, which is mutated in multiple human cancers [1].in vitro: N/Ain vivo: N/AClinical trial: N/A
别名;IDH-C35;AGI5198;AGI 5198;IDH C35;N-Cycohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide; N-[2-(Cyclohexylamino)-1-(2-methylphenyl)-2-oxoethyl]-N-(3-fluorophenyl)-2-methyl-1H-imidazole-1-acetamide
搜索质检报告(COA)
搜索MSDS
相关产品